Welcome back to Oncology for the Inquisitive Mind's ongoing coverage of ESMO 2023. In the spirit of a worldwide oncology conference, here we present results from three very exciting trials in the early breast phase. Will immunotherapy begin to carve out a niche in early, high-risk, ER-positive breast cancer? Can atezolizumab demonstrate a benefit in early TNBC, and expand its own territory? Is abemaciclib pulling away from its rivals in the treatment of high-risk, ER-positive breast cancer? Will managing early breast cancer eventually have a similar success rate to the management of diabetes? And, most importantly, is Michelangelo a better Ninja Turtle than Donatello? The answers to all these questions, and more, lie within.
Studies discussed in this episode (subscription may be required):
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}